Cat. No.: HY-119624

Copy Link Print Information

MOMIPP

Customer Review

Based on 1 Customer Validation

MOMIPP, a macropinocytosis inducer, is a PIKfyve inhibitor. MOMIPP penetrates the blood-brain barrier (BBB).

For research use only. We do not sell to patients.

Purity: 99.00%
CAS No.: 1363421-46-8
Formula: C₁₈H₁₆N₂O₂
Molecular Weight:292.33

Storage:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

MOMIPP Chemical Structure

CAS No.: 1363421-46-8

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

MOMIPP, a macropinocytosis inducer, is a PIKfyve inhibitor. MOMIPP penetrates the blood-brain barrier (BBB)^[1]^[2].

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	IC₅₀	5.02 μM Compound: 1; MOMIPP	Antiproliferative activity against human A375 cells after 48 hrs by MTS assay Antiproliferative activity against human A375 cells after 48 hrs by MTS assay	[PMID: 29878764]
A549	IC₅₀	>10 μM Compound: 1; MOMIPP	Antiproliferative activity against human A549 cells after 48 hrs by MTS assay Antiproliferative activity against human A549 cells after 48 hrs by MTS assay	[PMID: 29878764]
BGC-823	IC₅₀	>10 μM Compound: 1; MOMIPP	Antiproliferative activity against human BGC823 cells after 48 hrs by MTS assay Antiproliferative activity against human BGC823 cells after 48 hrs by MTS assay	[PMID: 29878764]
HCC1806	IC₅₀	>10 μM Compound: 1a; MOMIPP	Antiproliferative activity against human HCC1806 cells assessed as inhibition of cell proliferation incubated for 24 hrs by SRB assay Antiproliferative activity against human HCC1806 cells assessed as inhibition of cell proliferation incubated for 24 hrs by SRB assay	[PMID: 37212861]
HCT-116	IC₅₀	>10 μM Compound: 1; MOMIPP	Antiproliferative activity against human HCT116 cells after 48 hrs by MTS assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTS assay	[PMID: 29878764]
HeLa	IC₅₀	1.22 μM Compound: MOMIPP	Antiproliferative activity against human HeLa cells assessed as inhibition of cell viability incubated for 24 hrs by CCK8 assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell viability incubated for 24 hrs by CCK8 assay	[PMID: 38117948]
HepG2	IC₅₀	>10 μM Compound: 1; MOMIPP	Antiproliferative activity against human HepG2 cells after 48 hrs by MTS assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTS assay	[PMID: 29878764]
MCF-10A	IC₅₀	>10 μM Compound: 1; MOMIPP	Cytotoxicity against human MCF10A cells assessed as reduction in cell viability after 48 hrs by MTS assay Cytotoxicity against human MCF10A cells assessed as reduction in cell viability after 48 hrs by MTS assay	[PMID: 29878764]
MCF7	IC₅₀	>10 μM Compound: 1; MOMIPP	Antiproliferative activity against human MCF7 cells after 48 hrs by MTS assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTS assay	[PMID: 29878764]
MDA-MB-231	IC₅₀	>10 μM Compound: 1; MOMIPP	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTS assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTS assay	[PMID: 29878764]
MDA-MB-231	IC₅₀	0.88 μM Compound: MOMIPP	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 24 hrs by CCK8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 24 hrs by CCK8 assay	[PMID: 38117948]
MDA-MB-435S	IC₅₀	>10 μM Compound: 1; MOMIPP	Antiproliferative activity against human MDA-MB-435S cells after 48 hrs by MTS assay Antiproliferative activity against human MDA-MB-435S cells after 48 hrs by MTS assay	[PMID: 29878764]
SK-MEL-28	IC₅₀	8.156 μM Compound: 1; MOMIPP	Antiproliferative activity against human SK-MEL-28 cells after 48 hrs by MTS assay Antiproliferative activity against human SK-MEL-28 cells after 48 hrs by MTS assay	[PMID: 29878764]
SK-MEL-30	IC₅₀	>10 μM Compound: 1; MOMIPP	Antiproliferative activity against human SK-MEL-30 cells after 48 hrs by MTS assay Antiproliferative activity against human SK-MEL-30 cells after 48 hrs by MTS assay	[PMID: 29878764]
U-251	GI₅₀	2.1 μM Compound: 1, MOMIPP	Growth inhibition of human U251 cells preincubated for 24 hrs followed by compound-washout measured at 48 hrs by sulforhodamine assay Growth inhibition of human U251 cells preincubated for 24 hrs followed by compound-washout measured at 48 hrs by sulforhodamine assay	[PMID: 24527179]
U-251	GI₅₀	2.3 μM Compound: 1a	Induction of methuosis in human U251 cells after 4 to 48 hrs by phase contrast microscopic analysis Induction of methuosis in human U251 cells after 4 to 48 hrs by phase contrast microscopic analysis	[PMID: 27343855]
U-251	GI₅₀	2.32 μM Compound: 1a	Growth inhibition of human U251 cells after 48 hrs by sulforhodamine B colorimetric assay Growth inhibition of human U251 cells after 48 hrs by sulforhodamine B colorimetric assay	[PMID: 27343855]
U-251	GI₅₀	2.32 μM Compound: 1a, MOMIPP	Growth inhibition of human U251 cells after 24 hrs sulphorhodomine B colorimetric assay Growth inhibition of human U251 cells after 24 hrs sulphorhodomine B colorimetric assay	[PMID: 25654321]
U-251	IC₅₀	1.9 μM Compound: 19, MOMIPP	Cytotoxicity against human U251 cells after 24 hrs by MTT assay Cytotoxicity against human U251 cells after 24 hrs by MTT assay	[PMID: 22335538]

In Vitro

MOMIPP can induce intense macropinocytosis, leading to methuosis in cultured glioblastoma cells at low micromolar concentrations^[1].
In U373 and Hs683 cell lines, 3 μM for MOMIPP induces cell vacuolization^[1].
MOMIPP (10 μM) causes early disruptions of glucose uptake and glycolytic metabolism. MOMIPP selectively activates the JNK1/2 stress kinase pathway, resulting in phosphorylation of c-Jun, Bcl-2 and Bcl-xL^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[2]

Cell Line:

U251 cells
Concentration:

10 μM
Incubation Time:

4 h or 24 h
Result:

Activated the JNK stress kinase pathway.

In Vivo

MOMIPP (80 mg/kg; i.p.; once daily; for 15 consecutive days) shows moderately effective in suppressing progression of intracerebral glioblastoma xenografts^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Athymic CrTac:NCR-Foxn1 mice (female, 7-8 weeks)^[2]
Dosage:

80 mg/kg
Administration:

i.p.; once daily; for 15 consecutive days
Result:

Suppressed progression of intracerebral glioblastoma xenografts.

Chemical Information

CAS No. 1363421-46-8
Appearance Solid
Molecular Weight 292.33
Formula C₁₈H₁₆N₂O₂
Color Yellow to orange
SMILES

O=C(/C=C/C1=C(NC2=C1C=C(C=C2)OC)C)C3=CC=NC=C3
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 31.25 mg/mL (106.90 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.4208 mL

17.1040 mL

34.2079 mL

5 mM

0.6842 mL

3.4208 mL

6.8416 mL

10 mM

0.3421 mL

1.7104 mL

3.4208 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (274 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Margaux Colin, et al. Dysregulation of Macropinocytosis Processes in Glioblastomas May Be Exploited to Increase Intracellular Anti-Cancer Drug Levels: The Example of Temozolomide. Cancers (Basel). 2019 Mar 22;11(3):411. [Content Brief]

[2]. Zehui Li, et al. The JNK signaling pathway plays a key role in methuosis (non-apoptotic cell death) induced by MOMIPP in glioblastoma. BMC Cancer. 2019 Jan 16;19(1):77. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.4208 mL	17.1040 mL	34.2079 mL	85.5198 mL
	5 mM	0.6842 mL	3.4208 mL	6.8416 mL	17.1040 mL
	10 mM	0.3421 mL	1.7104 mL	3.4208 mL	8.5520 mL
	15 mM	0.2281 mL	1.1403 mL	2.2805 mL	5.7013 mL
	20 mM	0.1710 mL	0.8552 mL	1.7104 mL	4.2760 mL
	25 mM	0.1368 mL	0.6842 mL	1.3683 mL	3.4208 mL
	30 mM	0.1140 mL	0.5701 mL	1.1403 mL	2.8507 mL
	40 mM	0.0855 mL	0.4276 mL	0.8552 mL	2.1380 mL
	50 mM	0.0684 mL	0.3421 mL	0.6842 mL	1.7104 mL
	60 mM	0.0570 mL	0.2851 mL	0.5701 mL	1.4253 mL
	80 mM	0.0428 mL	0.2138 mL	0.4276 mL	1.0690 mL
	100 mM	0.0342 mL	0.1710 mL	0.3421 mL	0.8552 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

MOMIPP

Kinase Inhibitor Library

PI3K/Akt/mTOR Compound Library

Anti-Cancer Compound Library

CNS-Penetrant Compound Library

Anti-Aging Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Glucose Metabolism Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

MOMIPP

Kinase Inhibitor Library

PI3K/Akt/mTOR Compound Library

Anti-Cancer Compound Library

CNS-Penetrant Compound Library

Anti-Aging Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Glucose Metabolism Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

MOMIPP Related Classifications

Cat. No.: HY-119624